Helus Pharma CEO to Present at Prestigious H.C. Wainwright Conference, Highlighting Pipeline Progress

Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company dedicated to developing novel serotonergic agonists (NSAs) for mental health conditions, has announced that its CEO, Michael Halstead, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. Scheduled to take place from September 14-16, 2026, in New York City, the conference is a key event for the investment community, providing a platform for emerging companies to showcase their progress and future plans. The fireside chat is set to be webcast live on September 14 at 9 a.m. EDT, with a replay available on the Events & Presentations page of Helus Pharma’s investor relations website.

This announcement carries significant weight for Helus Pharma as it navigates the competitive landscape of mental health therapeutics. The company's focus on NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity—positions it at the forefront of a potential paradigm shift in treating depression and anxiety. With a robust pipeline, including HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD), and HLP004, another proprietary NSA in Phase 2 for generalized anxiety disorder (GAD), the company is advancing candidates that have the potential to address unmet medical needs. Notably, HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA), which underscores its potential to offer significant improvement over existing therapies.

The participation of CEO Michael Halstead at this prestigious conference is more than a routine corporate appearance; it signals the company's commitment to transparency and investor engagement. For investors, this is an opportunity to gain insights into Helus Pharma's strategic direction, clinical milestones, and future catalysts. The fireside chat format allows for a deeper discussion of the company's pipeline, regulatory interactions, and market opportunities. This is particularly crucial as the company continues to develop its NSAs and expand its research portfolio, which includes additional investigational candidates.

The timing of the conference is also notable, as it comes at a period when the mental health treatment landscape is evolving. Traditional antidepressants often have delayed onset of action and significant side effects, leaving many patients with inadequate relief. Helus Pharma's NSAs aim to provide rapid and durable improvements, potentially transforming how mental health conditions are managed. The company's commitment to innovation is reflected in its global operations across Canada, the United States, the United Kingdom, and Ireland, and its proprietary technology platform.

For the investment community, conferences like H.C. Wainwright's are vital for assessing a company's viability and growth prospects. Helus Pharma's presence highlights its proactive approach to communicating with current and potential shareholders. The live webcast and replay ensure that a broad audience can access the discussion, aligning with the company's efforts to maintain transparency. As the company continues to progress its clinical programs, events like this serve as critical touchpoints for stakeholders to evaluate the company's trajectory and the potential impact of its therapies on the mental health landscape.

Investors and industry observers will be keen to hear updates on the Phase 3 trial for HLP003 and the Phase 2 trial for HLP004, as well as any insights into the company's research and development strategy. The fireside chat may also address the company's financial position and upcoming milestones, providing a comprehensive overview of Helus Pharma's potential for growth. In a sector where innovation is key, Helus Pharma's dedication to developing novel treatments for mental health conditions positions it as a company to watch. The H.C. Wainwright conference provides a stage for the company to articulate its vision and progress, potentially attracting new investors and strengthening confidence among existing ones. As the event approaches, all eyes will be on the insights and announcements that emerge from this fireside chat.